Silence Therapeutics plc (SLN) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
SLN's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
SLN Revenue Analysis (2013–2024)
As of March 1, 2026, Silence Therapeutics plc (SLN) generated trailing twelve-month (TTM) revenue of $24.9 million, reflecting significant decline in growth of -86.1% year-over-year. The most recent quarter (Q3 2025) recorded $159,000 in revenue, down 29.0% sequentially.
Looking at the longer-term picture, SLN's 5-year compound annual growth rate (CAGR) stands at +181.7%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $43.3 million in 2024, representing a new all-time high.
Revenue diversification analysis shows SLN's business is primarily driven by Research Collaboration Income (100%), and Royalty Income (0%). With over half of revenue concentrated in Research Collaboration Income, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), SLN has underperformed the peer group in terms of revenue growth. Compare SLN vs ALNY →
Peer Comparison
Compare SLN's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SLNCurrent | $25M | -86.1% | +181.7% | -146.4% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $43.3M | +70.5% | $31.4M | 72.7% | $-63,319,000 | -146.4% |
| 2023 | $25.4M | +17.2% | $15.1M | 59.3% | $-49,604,000 | -195.5% |
| 2022 | $21.7M | +74.4% | $8.2M | 37.8% | $-61,040,000 | -281.9% |
| 2021 | $12.4M | +126.6% | $5.0M | 39.9% | $-45,814,000 | -369.0% |
| 2020 | $5.5M | +2145.5% | $1.7M | 31.3% | $-35,847,000 | -654.3% |
| 2019 | $244K | - | $244K | 100.0% | $-22,734,000 | -9317.2% |
| 2018 | $0 | -100.0% | $-9,743,000 | - | $-20,571,000 | - |
| 2017 | $16K | -97.9% | $-7,927,000 | -49543.8% | $-14,391,000 | -89943.8% |
| 2016 | $770K | - | $-7,941,000 | -1031.3% | $-11,906,000 | -1546.2% |
| 2015 | $0 | -100.0% | $-7,114,000 | - | $-9,769,000 | - |
See SLN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SLN vs AGIO
See how SLN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SLN's revenue growth accelerating or slowing?
SLN revenue declined -86.1% year-over-year, contrasting with the 5-year CAGR of +181.7%. TTM revenue fell to $25M. This reverses the prior growth trend.
What is SLN's long-term revenue growth rate?
Silence Therapeutics plc's 5-year revenue CAGR of +181.7% reflects the variable expansion pattern. Current YoY growth of -86.1% is below this long-term average.
How is SLN's revenue distributed by segment?
SLN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.